Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …

BACKGROUND Passive immunotherapy with convalescent plasma (CP) is a potential
treatment for COVID-19. Evidence from controlled clinical trials is inconclusive. METHODS …

COVID-19 in immunocompromised hosts has emerged as a difficult therapeutic
management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 …

Importance There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in
patients hospitalized with COVID-19. Objective To determine the safety and efficacy of CCP …